Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
News|Articles|February 4, 2025
FDA Action Update, January 2025: Approvals, Clearances, and Designations
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in January 2025, making a number of decisions on potential new therapeutic agents including granting approvals, clearances, and acceptances, designations.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.
Advertisement
Advertisement